Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion.

Protein engineering, design & selection : PEDS·2026

Same author

Exploiting siderophores and related proteins for antimicrobial strategies in Staphylococcus aureus: A review.

Bioorganic chemistry·2026

Same author

Dietary intake and food sources of choline in Koreans: findings from Korea National Health and Nutrition Examination survey 2018-2022.

Nutrition research and practice·2026

Same author

<i>Levilactobacillus brevis</i> KU15147 Attenuates MIA-Induced Osteoarthritis by Modulating Inflammatory Responses and Cartilage Metabolism.

Journal of microbiology and biotechnology·2026

Same author

Scalable Nanoemulsion Formation of Lipophilic Active Ingredients via Low-Energy Phase Inversion.

Polymers·2026

Same author

Bioavailability of lutein following short-term consumption of raw vegetables and juice.

Nutrition research and practice·2026

Search research articles

Related Experiment Video

Updated: Sep 15, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

T-Cell-Derived Extracellular Vesicles with an Antitransferrin Receptor Antibody for Multicancer Targeting.

Hanchae Cho¹, Hyunji Ju², Sanghee Shin³

¹Department of Biomedical Science, Kyungpook National University School of Medicine, Daegu 41944, Republic of Korea.

|July 15, 2025

Summary

Engineered T-cell-derived small extracellular vesicles (T-EVs) show enhanced cancer cell targeting and reduced tumor growth. These T-EVs offer a promising strategy for developing novel targeted cancer therapies with minimal toxicity.

Keywords:

T-cell-derived small extracellular vesicles antibody surface modification targeted therapy transferrin receptor 1

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Sep 15, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Area of Science:

Immunology
Oncology
Nanomedicine

Background:

Small extracellular vesicles (sEVs) derived from immune cells are being investigated for anticancer properties.
Challenges remain in improving the targeting efficiency of sEVs for cancer therapy.

Purpose of the Study:

To engineer T-cell-derived sEVs with enhanced targeting capabilities for cancer cells.
To evaluate the in vitro and in vivo anticancer efficacy and safety of engineered T-EVs.

Main Methods:

T-cell-derived sEVs were engineered with antitransferrin receptor 1 (TfR1) antibodies to create T-EVs.
Targeting efficiency was assessed using flow cytometry, immunocytochemistry, and live cell imaging.
Anticancer effects were evaluated in cancer cell lines and mouse models, including assessment of PD-L1, Rab27a, and CD8+ T-cell responses.

Main Results:

T-EVs demonstrated enhanced delivery to six cancer cell types in vitro.
Systemic administration of T-EVs efficiently targeted breast, lung, and skin tumors in mouse models.
T-EVs significantly inhibited tumor growth without systemic toxicity, reduced PD-L1 and Rab27a levels, and enhanced CD8+ T-cell cytotoxicity and proliferation.

Conclusions:

Engineered T-EVs exhibit potent anticancer effects against multiple cancer types.
T-EVs represent a promising platform for targeted cancer therapy, improving drug delivery and immune response.
This study highlights the potential of T-EVs in overcoming current limitations in cancer treatment strategies.